GHのチャート
GHの企業情報
| symbol | GH |
|---|---|
| 会社名 | Genomic Health Inc （ゲノミック・ヘルス） |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Guardant Health Inc. is a United States-based company that engages in non-invasive cancer genomic sequencing. The Company is focused on developing diagnostic technologies that can transform cancer from a silent killer into a manageable disease. The Company engages in next-generation sequencing single-cell genomics and cancer diagnostics. The Company offers Guardant360 which is a biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options. The 73-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases and interrogates all four types of genomic alterations. The test prevents repeat invasive biopsies when cancer has progressed or recurred despite treatment or when an initial biopsy is unobtainable or has insufficient tissue. It is the circulating tumor DNA (ctDNA) test that includes all somatic genomic targets in a single test. ゲノミック・ヘルスは米国でがんの個別化治療のためのゲノム解析(遺伝子検査)を行う。侵潤性乳がん、結腸がん、前立腺がん用の腫瘍の大きさ、悪性度、再発性、化学療法の効果性などの情報を提供するオンコタイプDX検査を行う。また、他のがんに対するオンコタイプDX検査の臨床研究を行う。 Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. |
| 本社所在地 | 301 Penobscot Drive Redwood City CA 94063 USA |
| 代表者氏名 | AmirAli Talasaz アミアリタラサス |
| 代表者役職名 | President Chief Operating Officer Director |
| 電話番号 | +1 650-290-7575 |
| 設立年月日 | 36739 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 863人 |
| url | www.genomichealth.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gh |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） ー |
| 終値（lastsale） | 29.55 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 357.621 |
| 売上高 | 売上高（百万ドル） -- |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3294.422 |
| 当期純利益 | 当期純利益（百万ドル） -- |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Guardant Health Inc revenues increased 93% to $36.1M. Net loss applicable to common stockholders decreased 13% to $35.5M. Revenues reflect United States segment increase of 77% to $29.5M International segment increase from $2.1M to $6.6M. Lower net loss reflects G/L on early Exting of lease relat debt decrease from $5.1M (expense) to $0K Interest Exp-Net of Capitalized Interest decrease of 69% to $648K (expense). |
GHのテクニカル分析
GHのニュース
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer 2023/04/21 12:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023. “Despite multiple screening modalities for color
Guardant Health: On Hold For Now (NASDAQ:GH) 2023/04/20 23:57:09 Seeking Alpha
Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high. Click here for our GH review.
Guardant immunotherapy response test covered by Medicare 2023/04/18 12:59:59 Seeking Alpha
Medicare has agreed to cover Guardant Health (GH) Guardant360 Response test, which is used to assess a cancer patients response to immune checkpoint inhibitors.
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy 2023/04/18 12:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health receives Medicare coverage for Guardant360 Response™ to monitor cancer patient response to immunotherapy
Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy 2023/04/18 12:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test. Guardant360 Response is the first blood-only test that enables doctors to track molecular response through changes in circulating tumor DNA
Hedge Fund and Insider Trading News: Elliott Management, Accendo Capital, Haidar Capital Management, Odey Asset Management, Guardant Health Inc (GH), New Mountain Finance Corp. (NMFC), and More 2023/03/16 17:57:51 Insider Monkey
Elliott Boosts Stake in Triple Flag to 67% (Reuters) Elliott Investment Management on Thursday raised its stake in gold-focused streaming and royalty firm Triple Flag Precious Metals Corp to 67% from 64.7%. The hedge fund acquired 4.7 million shares in Triple Flag at C$16.50 per share. Triple Flag provides upfront financing to miners in exchange […]
Guardant Health Earnings Perspective: Return On Capital Employed 2023/03/16 14:46:37 Benzinga
According to Benzinga Pro data, during Q4, Guardant Health (NASDAQ: GH ) posted sales of $126.89 million. Earnings were up 13.62%, but Guardant Health still reported an overall loss of $139.93 million. Guardant Health collected $117.40 million in revenue during Q3, but reported earnings showed a $161.99 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company … Full story available on Benzinga.com
Guardant Health Submits Colorectal Cancer Screening Test to FDA for Premarket Approval 2023/03/10 15:29:17 GenomeWeb
The firm''s application is supported by data from the ECLIPSE study, which compared results of the Shield test to colonoscopy findings in 20,000 individuals.
Guardant seeks FDA approval of colorectal cancer detection blood test 2023/03/10 13:25:20 Seeking Alpha
Guardant Health (GH) submitted the final module of a premarket approval ((PMA)) application to the U.S
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test 2023/03/10 13:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC). The submission is comprised of data from the company’s positive ECLIPSE study, an over 20,000
Guardant Health: More Catalysts To Power Leaping Growth 2023/02/10 16:55:02 Seeking Alpha
Despite recent data hiccups for Guardant Health, you can expect much more upsides to GH stock. Click here for our take on GH and its prospects.
Guardant wins UnitedHealthcare coverage for cancer diagnostic test 2023/02/08 13:58:43 Seeking Alpha
Guardant Health (GH) announced Wednesday that UnitedHealth (UNH), has decided to cover its Guardant360 CDx liquid biopsy test for all of its commercial policies. Read the full story here.
Guardant Health receives coverage from UnitedHealthcare for Guardant360 CDx blood test as companion diagnostic in advanced lung and breast cancer 2023/02/08 13:05:00 Wallstreet:Online
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360 CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer 2023/02/08 13:05:00 Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced or metastatic breast or non-small cell lung cancer (NSCLC). T
Can you now get a good deal on Guardant Health Inc.’s shares? 2023/02/08 12:54:00 US Post News
Guardant Health Inc. (NASDAQ:GH) marked $28.56 per share on Tuesday, down from a previous closing price of $29.56. While Guardant Health Inc. has underperformed by -3.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GH fell by -60.88%, with highs and lows ranging from $78.34 to […]